Heptares' GPCR Discovery Pact With PeptiDream Focused On Inflammation

29 Jun 2017

• By Sten Stovall

An undisclosed G-protein coupled receptor playing a role in inflammatory disease will be the focus of a drug pact between Heptares and PeptiDream.

Heptares and PeptiDream Target Inflammation • Source: Shutterstock

In its latest technology alliance, Sosei Group Corp. subsidiary Heptares Therapeutics Ltd. has joined forces with PeptiDream Inc. to discover, develop and commercialize new drugs by targeting an undisclosed G protein-coupled receptor with an important role in inflammatory diseases.

Under the agreement, jointly announced June 29, the duo will jointly conduct and share the costs of the discovery and development program, each using their own proprietary technology...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Quick Listen: Scrip’s Five Must-Know Things

02 Jun 2025

• By Ian Haydock

In this week's episode: a preview of major ASCO readouts; Roivant stays patient in deals; Lilly diversifies pain pipeline with SiteOne acquisition; Nucala gets US COPD nod; and women in Indian pharma.

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

30 May 2025

• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

30 May 2025

• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

29 May 2025

• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

30 May 2025

• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.